AbbVie’s Humira is still on top, but biosimilars are chipping away at its dominance

The share of Ab­b­Vie’s brand-name ver­sion of Hu­mi­ra has dropped to 82% of the to­tal mar­ket, 13% less than in March, ac­cord­ing to a Sam­sung …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.